C-MGDDImmorta Bio
senescent cells, stem cells, personalized therapeutics
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-MGDD
C-MGDDC-MGDDsenescent cells, stem cells, personalized therapeutics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Immorta Bio states that aging itself is the root risk factor behind many major diseases and should be treated directly rather than only managing its downstream conditions. The company argues that conventional therapies for diseases of aging are insufficient because they mostly offer symptomatic relief, while a better approach is to use a patient’s own young stem cells and enhanced immune cells to restore the body’s youthful repair and defense mechanisms, potentially improving health outcomes, extending healthy lifespan, and enabling life extension.
SourceNo company beliefs, mission, or longevity theory are stated in the provided snapshot text. The page only says the website is in development and will be completed shortly.
SourceImmortaBio states that aging itself is the root cause of age-related diseases and should be treated as a disease, arguing that solving diseases of aging is effectively solving aging. The company presents aging as a cellular and organ-level pathophysiological process driven by recognized hallmarks such as stem cell exhaustion, senescence, inflammation, mitochondrial dysfunction, and telomere attrition. It further argues that symptom-focused modalities are insufficient, that existing stem-cell approaches have largely failed because allogeneic cells are rejected and autologous adult cells are old and limited, and that the most promising path is stem-cell-based healing using young, patient-derived personalized progenitor cells.
Source